A big part of Being Patient’s mission is to equip our community with the best possible information to navigate Alzheimer’s disease and other dementias,…
The science behind Alzheimer’s is constantly developing, but its cause remains elusive and the disease is frequently misdiagnosed. A 2017 study at a hospital…
A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal with dementia, there was a double…
The Price Is Right host Bob Barker has joined the list of TV personalities and celebrities who have passed away from Alzheimer’s disease, and…
Editor’s note: Dr. Marwan Sabbagh will join Being Patient again on September 19, 2023 to revisit this topic and discuss dementia misdiagnosis, why it’s…
If you could get a $400 blood test that tells you within 10 days whether you’re likely to develop Alzheimer’s disease years or decades…
Lewy body dementia is the second most common form of dementia. Where Alzheimer’s disease makes up 70 percent of dementia cases, Lewy body makes…
Beta-amyloid plaques — sticky globs of protein — build up in the brains of people with Alzheimer’s disease. For decades, scientists have focused on…
Vaccines are one of the greatest medical advances in history, and now, this strategy is being applied to the treatment and prevention of Alzheimer’s….
Research shows that certain widely distributed vaccines may offer benefits beyond just immunity against an infection: one might be helping to fend off Alzheimer’s….
Right now, a definitive Alzheimer’s diagnosis can only be obtained through the detection of beta-amyloid levels in the brain — clumps of a protein…
There are dozens of new approaches to treating Alzheimer’s currently in clinical trials. But while some promising innovations in diagnostics and intervention are progressing…
Alzheimer’s disease affects one in every three people over the age of 85, and the scale of the epidemic is only worsening. While there…
Clinical trials and studies scientific experiments that investigate new treatments, lifestyle interventions, or risk factors for developing a disease like Alzheimer’s or dementia. By…
In January of 2023, the Food and Drug Administration approved the second anti-amyloid therapy for Alzheimer’s disease, Leqembi (generic name lecanemab). A new Alzheimer’s…